As an investor in Sangamo (SGMO) the very slow and cautious pace of regulatory action at the U.S. Food & Drug Administration is frustrating. The FDA has only slowly allowed the company to expand the number of patients enrolled in the the safety trials for its new in vivo gene editing technology. As a human […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
